LIMN: Liminatus Pharma Corp Net earnings per share (EPS TTM)

Liminatus Pharma LLC (LIMN) - corporate logo

Liminatus Pharma (LIMN) possesses high scientific authority in the field of oncoimmunology, developing cutting-edge methods to combat severe tumors. The annual earnings per share trend demonstrates that the current status equals -21.59. The company is implementing AI for molecular design during automated synthesis, and its laboratory capacities are functioning strictly according to schedule, maintaining full operational readiness.

LIMN Liminatus Pharma Net earnings per share for the last 12 months (05/02/2025 - 11/17/2026)

Summary analytical data breakdowns for Liminatus (LIMN)

- share price and expert price forecast:
Fundamental valuation:LIMN - Liminatus
Flagship merchandise of Liminatus Pharma Corp

Institutional managers evaluate the profile of Liminatus Pharma (LIMN) through the lens of real capital generation efficiency. This metric reflects the net profit distributed per share over a rolling year, allowing them to filter out market noise from fundamental stability. By analyzing the rolling year earnings per share, an investor sees the actual specific income of the business. For a biopharmaceutical brand in the field of cancer immunotherapy, this metric confirms the financial viability of its scientific developments. Steady growth of this indicator guarantees the asset's reliability even amidst high sector volatility.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year IMMX|alxoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year CUE (Cue Biopharma)|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)